Who Owns Insight Molecular Diagnostics Stock?
NASDAQ: IMDXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 56.43%
- Held by insiders
- 21.00%
- Institutional holders
- 47
- Institutions 56.4%
- Insiders 21.0%
- Public and other 22.6%
Who owns Insight Molecular Diagnostics stock?
Institutional investors own about 56.4% of Insight Molecular Diagnostics's shares, spread across 47 institutions that file 13F reports. That level of institutional ownership is moderate. Insiders, including executives, directors and large founding shareholders, hold 21.00% of IMDX.
The largest institutional holders are Broadwood Capital, Inc. (38.76%), AWM Investment Company, Inc. (8.67%) and Vanguard Capital Management LLC (2.25%). Together, the top 10 institutions control 55.0% of shares outstanding. In their latest filings, 6 of the top 10 institutions increased their IMDX positions and 4 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of IMDX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Broadwood Capital, Inc. | 12.68M | 38.76% | +6.3% |
| AWM Investment Company, Inc. | 2.84M | 8.67% | +1.1% |
| Vanguard Capital Management LLC | 735.85K | 2.25% | +37.0% |
| Pura Vida Investments, Llc | 484.85K | 1.48% | -48.8% |
| Family Office Research LLC | 368.85K | 1.13% | +189.8% |
| Geode Capital Management, LLC | 256.90K | 0.79% | -2.0% |
| FNY Investment Advisers, LLC | 182.56K | 0.56% | -26.2% |
| Jane Street Group, LLC | 157.68K | 0.48% | +100.0% |
| Blackrock Inc. | 150.52K | 0.46% | +11.2% |
| Vanguard Fiduciary Trust Co | 124.58K | 0.38% | -6.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of IMDX
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 475.40K | 1.45% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 248.06K | 0.76% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 108.02K | 0.33% |
| iShares Trust-iShares Micro-Cap ETF | 42.97K | 0.13% |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 38.62K | 0.12% |
| Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund | 36.13K | 0.11% |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 19.49K | 0.06% |
| VANGUARD VALLEY FORGE FUNDS-Vanguard Balanced Index Fund | 7.93K | 0.02% |
| VANGUARD Inst. INDEX Fd.S-Vanguard Inst. Total Stock Market Index Fd. | 4.46K | 0.01% |
| EQ Advisors Trust-1290 VT Micro Cap Portfolio | 2.90K | 0.01% |
Frequently asked questions
Who is the largest shareholder of Insight Molecular Diagnostics?
Broadwood Capital, Inc. is the largest institutional shareholder of IMDX, owning 38.76% of shares outstanding (12.68M shares) as of its latest 13F filing.
What percentage of Insight Molecular Diagnostics is owned by institutions?
Institutions own about 56.4% of IMDX shares and 71.4% of the public float.
How much of Insight Molecular Diagnostics do insiders own?
Insiders, such as officers and directors, own about 21.00% of IMDX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.